InflaRx to Participate in Major Healthcare Conference
InflaRx N.V. (NASDAQ: IFRX), a leading biopharmaceutical entity specializing in anti-inflammatory treatments, is set to make a significant appearance at a notable healthcare conference. This event, the Guggenheim Securities 2nd Annual Healthcare Innovation Conference, is scheduled to take place soon.
Details About the Conference
The conference will be held from November 10 to 12 in a prominent venue in Boston. InflaRx has a dedicated slot for a fireside chat on November 11, which will commence at 2:30 PM ET. This discussion aims to provide insights into the company’s innovative strategies and ongoing projects in the biopharmaceutical space.
One-on-One Investor Meetings
In addition to the scheduled discussions, InflaRx will also facilitate one-on-one meetings with investors on the same day. This initiative underscores the company's commitment to engaging with its investors, presenting an opportunity to delve deeper into its business model and therapeutic developments.
Exploring InflaRx's Pioneering Therapeutics
InflaRx stands at the forefront of biopharmaceutical advancements through its targeted approach to anti-inflammatory treatments. Utilizing cutting-edge technologies, including proprietary anti-C5a and anti-C5a receptor technologies, the company has made remarkable strides in developing potent inhibitors that address the complement activation factor C5a. This factor plays a vital role in various inflammatory diseases.
Among its notable advancements is vilobelimab, an intravenously administered, first-in-class monoclonal antibody. This innovative therapy selectively binds to free C5a, demonstrating a transformative approach in treating inflammatory conditions. Clinical studies have exhibited both disease-modifying activity and favorable tolerability, making vilobelimab a prime candidate in therapeutic interventions.
Continuing Research and Development
Moreover, InflaRx is expanding its portfolio with INF904, an orally administered small molecule designed to suppress C5a-induced signaling. This ongoing research reflects the company’s dedication to tackling inflammation on multiple fronts, solidifying its position in the biopharmaceutical landscape.
Company Background
Founded in 2007, InflaRx has established a robust presence with operational hubs in Jena and Munich, Germany, and Ann Arbor, MI, USA. The company is committed to advancing healthcare through innovative research and development. For further insights about their work and advancements, interested parties can explore their official website.
Contact Information
For inquiries, you can reach out to:
InflaRx N.V.
Jan Medina, CFA
Vice President, Head of Investor Relations
Email: IR@inflarx.de
MC Services AG
Katja Arnold, Laurie Doyle, Dr. Regina Lutz
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
U.S.: +1-339-832-0752
Frequently Asked Questions
What is the significance of the Guggenheim Securities conference?
The conference serves as a platform for firms like InflaRx to showcase their innovations and engage with investors.
What are the main products developed by InflaRx?
InflaRx focuses on anti-inflammatory therapeutics, particularly vilobelimab and INF904.
How can investors learn more about InflaRx’s developments?
Investors can attend the conference's events or access the live stream of presentations and discussions.
Where is InflaRx headquartered?
InflaRx has its headquarters in Jena, Germany, alongside operational offices in Munich and Ann Arbor, MI, USA.
Who can be contacted for investor relations at InflaRx?
Jan Medina is the Vice President and Head of Investor Relations, reachable via email for inquiries.
